Market closed
Foghorn Therapeutics/$FHTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Foghorn Therapeutics
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Ticker
$FHTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
116
Website
FHTX Metrics
BasicAdvanced
$221M
-
-$1.83
3.12
-
Price and volume
Market cap
$221M
Beta
3.12
52-week high
$9.53
52-week low
$2.70
Average daily volume
181K
Financial strength
Current ratio
4.773
Quick ratio
4.706
Long term debt to equity
-107.116
Total debt to equity
-138.12
Management effectiveness
Return on assets (TTM)
-20.45%
Return on equity (TTM)
212.95%
Valuation
Price to revenue (TTM)
7.759
Price to book
-7.82
Price to tangible book (TTM)
-7.82
Price to free cash flow (TTM)
-1.905
Growth
Revenue change (TTM)
-21.66%
Earnings per share change (TTM)
-25.60%
3-year revenue growth (CAGR)
209.94%
3-year earnings per share growth (CAGR)
-11.95%
What the Analysts think about FHTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Foghorn Therapeutics stock.
FHTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
FHTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
FHTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Foghorn Therapeutics stock?
Foghorn Therapeutics (FHTX) has a market cap of $221M as of January 31, 2025.
What is the P/E ratio for Foghorn Therapeutics stock?
The price to earnings (P/E) ratio for Foghorn Therapeutics (FHTX) stock is 0 as of January 31, 2025.
Does Foghorn Therapeutics stock pay dividends?
No, Foghorn Therapeutics (FHTX) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Foghorn Therapeutics dividend payment date?
Foghorn Therapeutics (FHTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Foghorn Therapeutics?
Foghorn Therapeutics (FHTX) has a beta rating of 3.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.